Renal Biomarkers Market by Marker Type (Blood Urea Nitrogen, Creatinine, Cystatin C), Assay Platform Type (Enzymatic Assay, Enzyme-Linked Immunosorbent Assay (ELISA), Turbidimetric Immunoassay), Application, End-User - Global Forecast 2024-2030

Renal Biomarkers Market by Marker Type (Blood Urea Nitrogen, Creatinine, Cystatin C), Assay Platform Type (Enzymatic Assay, Enzyme-Linked Immunosorbent Assay (ELISA), Turbidimetric Immunoassay), Application, End-User - Global Forecast 2024-2030


The Renal Biomarkers Market size was estimated at USD 1.33 billion in 2023 and expected to reach USD 1.43 billion in 2024, at a CAGR 7.72% to reach USD 2.24 billion by 2030.

Global Renal Biomarkers Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Renal Biomarkers Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Renal Biomarkers Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Renal Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca PLC, Bayer AG, Bio-Rad Laboratories, Inc., bioMérieux SA, BioPorto Diagnostics A/S, Cipla Limited, Danaher Corporation, DiaSorin S.p.A., Eli Lilly and Co, Enzo Biochem, Inc., Eurofins Viracor Inc., F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, Novartis AG, Novatein Biosciences Inc., PerkinElmer Inc., Randox Laboratories Ltd., Renalytix AI PLC, Sanofi-Aventis, LLC., Sekisui Diagnostics, LLC, Siemens Healthineers AG, SphingoTec GmbH, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage



This research report categorizes the Renal Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

Marker Type
Blood Urea Nitrogen
Creatinine
Cystatin C
Neutrophil Gelatinase-Associated Lipocalin
Assay Platform Type
Enzymatic Assay
Enzyme-Linked Immunosorbent Assay (ELISA)
Turbidimetric Immunoassay
Application
Diagnosis & Disease Progression Monitoring
Research
End-User
Diagnostic Laboratories
Hospitals
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Renal Biomarkers Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Renal Biomarkers Market?
3. What are the technology trends and regulatory frameworks in the Renal Biomarkers Market?
4. What is the market share of the leading vendors in the Renal Biomarkers Market?
5. Which modes and strategic moves are suitable for entering the Renal Biomarkers Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Renal Biomarkers Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of renal disorders among population
5.1.1.2. Growing initiatives to create awareness on renal diseases and renal biomarkers
5.1.1.3. Trend towards developing personalized medicines and targeted therapies
5.1.2. Restraints
5.1.2.1. High costs associated with renal biomarkers
5.1.3. Opportunities
5.1.3.1. Robust research activities to introduce new renal biomarkers
5.1.3.2. Emerging technological advancements in renal surgeries
5.1.4. Challenges
5.1.4.1. Concerns over failure of biomarkers
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Renal Biomarkers Market, by Marker Type
6.1. Introduction
6.2. Blood Urea Nitrogen
6.3. Creatinine
6.4. Cystatin C
6.5. Neutrophil Gelatinase-Associated Lipocalin
7. Renal Biomarkers Market, by Assay Platform Type
7.1. Introduction
7.2. Enzymatic Assay
7.3. Enzyme-Linked Immunosorbent Assay (ELISA)
7.4. Turbidimetric Immunoassay
8. Renal Biomarkers Market, by Application
8.1. Introduction
8.2. Diagnosis & Disease Progression Monitoring
8.3. Research
9. Renal Biomarkers Market, by End-User
9.1. Introduction
9.2. Diagnostic Laboratories
9.3. Hospitals
10. Americas Renal Biomarkers Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Renal Biomarkers Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Renal Biomarkers Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. AstraZeneca PLC
14.1.3. Bayer AG
14.1.4. Bio-Rad Laboratories, Inc.
14.1.5. bioMérieux SA
14.1.6. BioPorto Diagnostics A/S
14.1.7. Cipla Limited
14.1.8. Danaher Corporation
14.1.9. DiaSorin S.p.A.
14.1.10. Eli Lilly and Co
14.1.11. Enzo Biochem, Inc.
14.1.12. Eurofins Viracor Inc.
14.1.13. F. Hoffmann-La Roche Ltd.
14.1.14. Fresenius Kabi AG
14.1.15. Novartis AG
14.1.16. Novatein Biosciences Inc.
14.1.17. PerkinElmer Inc.
14.1.18. Randox Laboratories Ltd.
14.1.19. Renalytix AI PLC
14.1.20. Sanofi-Aventis, LLC.
14.1.21. Sekisui Diagnostics, LLC
14.1.22. Siemens Healthineers AG
14.1.23. SphingoTec GmbH
14.1.24. Thermo Fisher Scientific Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
FIGURE 1. RENAL BIOMARKERS MARKET RESEARCH PROCESS
FIGURE 2. RENAL BIOMARKERS MARKET SIZE, 2023 VS 2030
FIGURE 3. RENAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. RENAL BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. RENAL BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. RENAL BIOMARKERS MARKET DYNAMICS
FIGURE 7. RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2023 VS 2030 (%)
FIGURE 8. RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2023 VS 2030 (%)
FIGURE 10. RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 12. RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 14. RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. RENAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. RENAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings